Advertisement
Research Article| Volume 50, ISSUE 4, P729-735, April 2009

Incidence of hepatocellular carcinoma in hepatitis C carriers with normal alanine aminotransferase levels

Published:January 06, 2009DOI:https://doi.org/10.1016/j.jhep.2008.11.019

      Background/Aims

      This study sought to identify the independent risk factors involved in the development of hepatocellular carcinoma (HCC) in patients with chronic hepatitis C virus (HCV) infection who have normal alanine aminotransferase (ALT) levels.

      Methods

      A total of 519 patients with average ALT integration values less than or equal to 40 IU/L over 10 years were included. Baseline ultrasound was done in all patients and 68 patients underwent liver biopsy at the start of this study. Factors associated with the cumulative incidence of HCC were determined.

      Results

      HCC occurred in 48 of 519 patients (9.2%). The following factors were significantly associated with the incidence of HCC: age > 65 years (adjusted hazard ratio: 2.006 [95% confidence interval: 1.078–3.733]), ALT > 20 IU/L (6.242 [1.499–25.987]), platelet count < 15.0 × 104/m3 (2.675 [1.407–5.085]), total bilirubin > 1.2 mg/dL (2.798 [1.257–6.228]), ALP > 338 IU/L (2.486 [1.327–4.657]), and total albumin < 3.5 g/dl (2.707 [1.177–6.223]). The 5- and 10-year cumulative incidences of HCC were 4.4% and 26.5% in patients with ALT > 20 IU/L and platelet count < 15.0 × 104/m3, respectively.

      Conclusions

      High ALT level and low platelet count are closely associated with the development of hepatocarcinogenesis. Therefore, individuals within this group are candidates for antiviral therapy.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Hepatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kiyosawa K.
        • Sodeyama T.
        • Tanaka E.
        • Gibo Y.
        • Yoshizawa K.
        • Nakano Y.
        • et al.
        Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus.
        Hepatology. 1990; 12: 671-675
        • Takano S.
        • Yokosuka O.
        • Imazeki F.
        • Tagawa M.
        • Omata M.
        Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients.
        Hepatology. 1995; 21: 650-655
        • Oka H.
        • Kurioka N.
        • Kim K.
        • Kanno T.
        • Kuroki T.
        • Mizoguchi Y.
        • et al.
        Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis.
        Hepatology. 1990; 12: 680-687
        • Ikeda K.
        • Saitoh S.
        • Koida I.
        • Arase Y.
        • Tsubota A.
        • Chayama K.
        • et al.
        A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis.
        Hepatology. 1993; 18: 47-53
        • Kaneko S.
        • Unoura M.
        • Takeuchi M.
        • Terasaki S.
        • Ogino H.
        • Matsushita E.
        • et al.
        The role of hepatitis C virus in hepatocellular carcinoma in Japan.
        Intervirology. 1994; 37: 108-113
        • Tarao K.
        • Shimizu A.
        • Ohkawa S.
        • Harada M.
        • Ito Y.
        • Tamai S.
        • et al.
        Development of hepatocellular carcinoma associated with increases in DNA synthesis in the surrounding cirrhosis.
        Gastroenterology. 1992; 103: 595-600
        • Tarao K.
        • Ohkawa S.
        • Shimizu A.
        • Harada M.
        • Nakamura Y.
        • Ito Y.
        • et al.
        Significance of hepatocellular proliferation in the development of hepatocellular carcinoma from anti-hepatitis C virus-positive cirrhotic patients.
        Cancer. 1994; 73: 1149-1154
        • Tarao K.
        • Takemiya S.
        • Tamai S.
        • Sugimasa Y.
        • Ohkawa S.
        • Akaike M.
        • et al.
        Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase levels in hepatectomized patients with hepatitis C virus-associated cirrhosis and HCC.
        Cancer. 1997; 79: 688-694
        • Tarao K.
        • Rino Y.
        • Ohkawa S.
        • Shimizu A.
        • Tamai S.
        • Miyakawa K.
        • et al.
        Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virus-associated cirrhosis.
        Cancer. 1999; 86: 589-595
        • Tarao K.
        • Rino Y.
        • Ohkawa S.
        • Tamai S.
        • Miyakawa K.
        • Takakura H.
        • et al.
        Close association between high serum alanine aminotransferase levels and multicentric hepatocarcinogenesis in patients with hepatitis C virus-associated cirrhosis.
        Cancer. 2002; 94: 1787-1795
        • Zanella A.
        • Conte D.
        • Prati D.
        • Mozzi F.
        • Capelli C.
        • Zanuso F.
        • et al.
        Hepatitis C virus RNA and liver histology in blood donors reactive to a single antigen by second-generation recombinant immunoblot assay.
        Hepatology. 1995; 21: 913-917
        • Prati D.
        • Capelli C.
        • Zanella A.
        • Mozzi F.
        • Bosoni P.
        • Pappalettera M.
        • et al.
        Influence of different hepatitis C virus genotypes on the course of asymptomatic hepatitis C virus infection.
        Gastroenterology. 1996; 110: 178-183
        • Puoti C.
        • Magrini A.
        • Stati T.
        • Rigato P.
        • Montagnese F.
        • Rossi P.
        • et al.
        Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels.
        Hepatology. 1997; 26: 1393-1398
        • Kumada T.
        • Toyoda H.
        • Kiriyama S.
        • Sone Y.
        • Tanikawa M.
        • Hisanaga Y.
        • et al.
        Relation between incidence of hepatic carcinogenesis and integration value of alanine aminotransferase in patients with hepatitis C virus infection.
        Gut. 2007; 56: 738-739
        • Okamoto H.
        • Mishiro S.
        • Tokita H.
        • Tsuda F.
        • Miyakawa Y.
        • Mayumi M.
        Superinfection of chimpanzees carrying hepatitis C virus of genotype II/1b with that of genotype III/2a or I/1a.
        Hepatology. 1994; 20: 1131-1136
        • Pawlotsky J.M.
        Use and interpretation of virological tests for hepatitis C.
        Hepatology. 2002; 36: S65-S73
        • Desmet V.J.
        • Gerber M.
        • Hoofnagle J.H.
        • Manns M.
        • Scheuer P.J.
        Classification of chronic hepatitis: diagnosis, grading and staging.
        Hepatology. 1994; 19: 1513-1520
        • Shen L.
        • Li J.Q.
        • Zeng M.D.
        • Lu L.G.
        • Fan S.T.
        • Bao H.
        Correlation between ultrasonographic and pathologic diagnosis of liver fibrosis due to chronic virus hepatitis.
        World J Gastroenterol. 2006; 28: 1292-1295
        • Iacobellis A.
        • Fusilli S.
        • Mangia A.
        • Clemente R.
        • Festa V.
        • Giacobbe A.
        • et al.
        Ultrasonographic and biochemical parameters in the non-invasive evaluation of liver fibrosis in hepatitis C virus chronic hepatitis.
        Aliment Pharmacol Ther. 2005; 22: 769-774
        • Matsui O.
        • Kadoya M.
        • Kameyama T.
        • Yoshikawa J.
        • Takashima T.
        • Nakanuma Y.
        • et al.
        Benign and malignant nodules in cirrhotic livers: distinction based on blood supply.
        Radiology. 1991; 178: 493-497
        • Prati D.
        • Taioli E.
        • Zanella A.
        • Della Torre E.
        • Butelli S.
        • Del Vecchio E.
        • et al.
        Updated definitions of healthy ranges for serum alanine aminotransferase levels.
        Ann Intern Med. 2002; 137: 1-10
        • Elinav E.
        • Ben-Dov I.Z.
        • Ackerman E.
        • Kiderman A.
        • Glikberg F.
        • Shapira Y.
        • et al.
        Correlation between serum alanine aminotransferase activity and age: an inverted U curve pattern.
        Am J Gastroenterol. 2005; 100: 2201-2204
        • Kim H.C.
        • Nam C.M.
        • Jee S.H.
        • Han K.H.
        • Oh D.K.
        • Suh I.
        Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study.
        BMJ. 2004; 328: 983
        • Lu S.N.
        • Wang J.H.
        • Liu S.L.
        • Hung C.H.
        • Chen C.H.
        • Tung H.D.
        • et al.
        Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma.
        Cancer. 2006; 107: 2212-2222
      1. Laboratory Guidelines for Screening, Diagnosis, and Monitoring of Hepatic Injury. The National Academy of Clinical Biochemistry (NACB). Clinical Chemistry 2000 December.